AbbVie Inc. (BCBA:ABBV)

Market Cap	570.70T
Revenue (ttm)	81.74T
Net Income (ttm)	3.22T
Shares Out	n/a
EPS (ttm)	1,809.89
PE Ratio	177.35
Forward PE	16.36
Dividend	502.66 (1.49%)
Ex-Dividend Date	Oct 15, 2025

Volume	273
Average Volume	1,626
Open	34,300
Previous Close	33,840
Day's Range	33,280 - 34,500
52-Week Range	18,475 - 38,540
Beta	n/a
RSI	47.44
Earnings Date	Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD